Want to see SE:NANEXA full AI Analyst Report?

Nanexa AB (NANEXA) Price & Analysis

0 Followers

NANEXA Stock Chart & Stats

kr3.03

kr0.05(3.79%)

At close: Mar 06 4:00 PM EST

kr3.03

kr0.05(3.79%)

Day’s Range― - ―

52-Week Rangekr1.40 - kr6.88

Previous CloseN/A

Volume242.80K

Average Volume (3M)656.90K

Market Cap

kr967.76M

Enterprise Valuekr632.73

Total Cash (Recent Filing)kr52.56M

Total Debt (Recent Filing)kr795.00K

Price to Earnings (P/E)―

Beta0.11

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding164,585,050

10 Day Avg. Volume646,460

30 Day Avg. Volume656,902

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)6.83

Price to Sales (P/S)19.19

P/FCF Ratio-26.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr112.20M

Bulls Say, Bears Say

Bulls Say

Platform-Based ModelPharmaShell provides a focused technology platform that can be applied across injectable medicines rather than relying on one standalone product. If development programs progress, partnering, licensing, milestone and royalty structures could support scalable commercial monetization.

Very Low LeverageMinimal leverage preserves financial flexibility because relatively little cash is required for debt service and refinancing. This gives Nanexa more room to fund platform development or negotiate partnerships while reducing balance-sheet pressure during ongoing operating losses.

Losses NarrowingThe reduction in losses indicates some improvement from the company’s weakest recent performance, even though profitability remains unproven. Continued narrowing could extend its funding runway and improve the economics of advancing PharmaShell programs toward partnerships.

Bears Say

Persistent Cash BurnSustained operating and free-cash-flow deficits show that the business is not yet self-funding its activities. Continued cash burn can increase reliance on financing or partner funding, potentially limiting development pace and weakening negotiating flexibility.

Sharp Revenue DeclineA decline of this magnitude signals substantial volatility in the current revenue base and makes near-term commercial traction difficult to rely on. It raises execution risk for a partnering-led model because development income may not yet be consistent or scalable.

Negative ProfitabilityNegative operating, net and gross margins indicate that current activities are not covering their economic costs. Until margins recover, additional development progress may continue to consume capital and shareholder returns may remain pressured by ongoing losses.

Nanexa AB News

Nanexa AB’s Phase 1 Study on NEX-22A: A Potential Game-Changer for Diabetes Treatment?

Nanexa AB (($DE:40M)) announced an update on their ongoing clinical study. Study Overview: The recent clinical study by...

12M ago

40M

NANEXA FAQ

What was Nanexa AB’s price range in the past 12 months?

Nanexa AB lowest stock price was kr1.40 and its highest was kr6.88 in the past 12 months.

What is Nanexa AB’s market cap?

Nanexa AB’s market cap is kr967.76M.

When is Nanexa AB’s upcoming earnings report date?

Nanexa AB’s upcoming earnings report date is Nov 05, 2026 which is in 45 days.

How were Nanexa AB’s earnings last quarter?

Nanexa AB released its earnings results on Aug 27, 2026. The company reported -kr0.074 earnings per share for the quarter.

Is Nanexa AB overvalued?

According to Wall Street analysts Nanexa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanexa AB pay dividends?

Nanexa AB does not currently pay dividends.

What is Nanexa AB’s EPS estimate?

Nanexa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanexa AB have?

Nanexa AB has 164,585,050 shares outstanding.

What happened to Nanexa AB’s price movement after its last earnings report?

Nanexa AB reported an EPS of -kr0.074 in its last earnings report. Following the earnings report the stock price went up 6.312%.

Which hedge fund is a major shareholder of Nanexa AB?

Currently, no hedge funds are holding shares in SE:NANEXA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanexa AB

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.